top of page

Mark Strobeck,PH.D.

Dr. Strobeck was most recently Executive Vice President and Chief Operating Officer of Assertio Therapeutics, a fully integrated specialty pharmaceutical company focused on developing effective medicines for patients with acute and chronic pain.  Dr. Strobeck joined Assertio Therapeutics, after the acquisition of Zyla Life Sciences where he was Executive Vice President and Chief Operating Officer. Previously, Dr. Strobeck served in similar positions for several Pharmaceutical companies including Egalet Corporation, Corridor Pharmaceuticals, Topaz Pharmaceuticals, Trevena Inc., and GlaxoSmithKline. Before working at these healthcare companies, Dr. Strobeck was a venture capitalist at SR One Ltd., the wholly owned venture capital arm of GSK and Euclid SR Partners.  Dr. Strobeck earned a Ph.D. in Pharmacology and Cell Biophysics from the University of Cincinnati, completed a post-doctoral fellowship in Cardiovascular Medicine at the University of Pennsylvania, and received his Bachelor’s degree from St. Lawrence University

bottom of page